top of page
血液樣本檢測設備

Publications.

2025

  • Wang R, Li Y, Li Z, Wang J, Li L, Xiang J, Jia C, Peng X, Wang Y, Ma W, Wang LA. Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies. Clinical Nuclear Medicine. 2025 Apr 1;50(4):316-23.

  • Wang R, Kang W, Liu Z, Zheng Y, Sui H, Li L, Wang J, Xiang J, Peng X, Chen X, Zhu Z. Head-to-head comparison of [68Ga] Ga-NOTA-RM26 and [18F] FDG PET/CT in patients with gastrointestinal stromal tumors: a prospective study. Journal of Nuclear Medicine. 2025 Feb 1;66(2):201-6.

  • Xiong H, Wang R, Zhang H, Zhang Q, Qin Y, Du C, Zhang X, Ye J, Shi C, Shen H, Zhu Z. Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer. ACS nano. 2025 Jan 28.

  • Zhang J, Greifenstein L, Jakobsson V, Zan E, Klega A, Rösch F, Landvogt C, Mueller C, Baum RP. First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors. Theranostics. 2025 Jan 20;15(6):2510.

  • Chen Y, Zheng S, Zang J, Shao Z, Tu D, Liu Q, Chen X, Miao W, Zhang J. [68Ga] Ga-LNC1007 versus 2-[18F] FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study. European Journal of Nuclear Medicine and Molecular Imaging. 2025 Jan;52(2):683-92.

2024

  • Zhao, X.; Jakobsson, V.; Tao, Y.; Zhao, T.; Wang, J.; Khong, P. L.; Chen, X.; Zhang, J. Targeted Radionuclide Therapy in Glioblastoma. ACS Applied Materials and Interfaces 2024, 16 (31), 40391-40410, Review. DOI: 10.1021/acsami.4c07850 Scopus.

  • Zhao, L.; Pang, Y.; Zhou, Y.; Chen, J.; Fu, H.; Guo, W.; Xu, W.; Xue, X.; Su, G.; Sun, L.; et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduction and Targeted Therapy 2024, 9 (1), Article. DOI: 10.1038/s41392-024-01853-w Scopus.

  • Zang, J.; Yang, Y.; Chen, S.; Wang, C.; Chen, S.; Hu, S.; Cai, H.; Li, X.; Xu, N.; Chen, X.; et al. Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024, 65 (7), 1021-1026, Article. DOI: 10.2967/jnumed.123.266940 Scopus.

  • Zang, J.; Wang, G.; Zhao, T.; Liu, H.; Lin, X.; Yang, Y.; Shao, Z.; Wang, C.; Chen, H.; Chen, Y.; et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (3), 871-882, Article. DOI: 10.1007/s00259-023-06470-3 Scopus.

  • Xu, W.; Cai, J.; Peng, T.; Meng, T.; Pang, Y.; Sun, L.; Wu, H.; Zhang, J.; Chen, X.; Chen, H. Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT. Journal of Nuclear Medicine 2024, 65 (1), Article. DOI: 10.2967/jnumed.123.266329 Scopus.

  • Wu, G.; Xian, W.; You, Q.; Zhang, J.; Chen, X. AcousticRobots: Smart acoustically powered micro-/nanoswimmers for precise biomedical applications. Advanced Drug Delivery Reviews 2024, 207, Review. DOI: 10.1016/j.addr.2024.115201 Scopus.

  • Wen, X.; Wang, R.; Xu, P.; Shi, M.; Shang, Q.; Zeng, X.; Zeng, X.; Liu, J.; Wang, X.; Zhu, Z.; et al. Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (7), 2023-2035, Article. DOI: 10.1007/s00259-024-06634-9 Scopus.

  • Wei, Z.; Li, B.; Wen, X.; Jakobsson, V.; Liu, P.; Chen, X.; Zhang, J. Engineered Antibodies as Cancer Radiotheranostics. Advanced Science 2024, 11 (30), Review. DOI: 10.1002/advs.202402361 Scopus.

  • Wang, H.; Su, W.; He, L.; Wu, D.; Liu, N.; Zhu, J.; Zhang, J.; Zhang, W. Dual targeting heterodimer PET tracer [18F]AlF‑FAPI‑RGD in patients with rheumatoid arthritis: a pilot exploratory study. Theranostics 2024, 14 (18), 7042-7053, Article. DOI: 10.7150/thno.102627 Scopus.

  • Wang, G.; Xu, P.; Zhang, J.; Chen, X. Application progress of Evans blue modified radiopharmaceuticals for theranostics. Chinese Journal of Nuclear Medicine and Molecular Imaging 2024, 44 (1), 35-40, Article. DOI: 10.3760/cma.j.cn321828-20221107-00335 Scopus.

  • Tan, Y.; Li, J.; Zhao, T.; Zhou, M.; Liu, K.; Xiang, S.; Tang, Y.; Jakobsson, V.; Xu, P.; Chen, X.; et al. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (9), 2761-2773, Article. DOI: 10.1007/s00259-024-06703-z Scopus.

  • Scott, A. M.; Zeglis, B. M.; Lapi, S. E.; Scott, P. J. H.; Windhorst, A. D.; Abdel-Wahab, M.; Giammarile, F.; Piaez, D.; Jalilian, A.; Knoll, P.; et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. The Lancet Oncology 2024, 25 (6), e250-e259, Review. DOI: 10.1016/S1470-2045(24)00037-8 Scopus.

  • Liu, N.; Wan, Q.; Wu, X.; Zhao, T.; Jakobsson, V.; Yuan, H.; Chen, X.; Zhang, J.; Zhang, W. A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (6), 1685-1697, Article. DOI: 10.1007/s00259-023-06587-5 Scopus.

  • Lin, R.; Wang, C.; Chen, S.; Lin, T.; Cai, H.; Chen, S.; Yang, Y.; Zhang, J.; Xu, F.; Zhang, J.; et al. [68Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (2), 535-547, Article. DOI: 10.1007/s00259-023-06436-5 Scopus.

  • Lapi, S. E.; Scott, P. J. H.; Scott, A. M.; Windhorst, A. D.; Zeglis, B. M.; Abdel-Wahab, M.; Baum, R. P.; Buatti, J. M.; Giammarile, F.; Kiess, A. P.; et al. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology. The Lancet Oncology 2024, 25 (6), e236-e249, Review. DOI: 10.1016/S1470-2045(24)00030-5 Scopus.

  • Kramer, C. S.; Zhang, J.; Baum, R. P. Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer—A case report. Frontiers in Medicine 2024, 11, Article. DOI: 10.3389/fmed.2024.1462234 Scopus.

  • Jiao, J.; Zhang, J.; Wen, W.; Qin, W.; Chen, X. Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection. Theranostics 2024, 14 (7), 2736-2756, Review. DOI: 10.7150/thno.95039 Scopus.

  • Jiang, W.; Wang, J.; Chen, L.; Qiu, X.; Du, C.; An, H.; Guo, X.; Wang, X.; Wang, J.; Li, P.; et al. Ultrasound-activated in situ click chemistry to trigger autophagosome tracking for enhanced autophagy blockade and synergistic cancer therapy. Aggregate 2024, 5 (4), Article. DOI: 10.1002/agt2.568 Scopus.

  • Hou, G.; Cheng, X.; Yang, Y.; Zhao, D.; Wang, G.; Zhao, H.; Zheng, R.; Wang, X.; Chen, X.; Chi, Y.; et al. Diagnostic performance and clinical impact of 18F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: A prospective single-center study. Theranostics 2024, 14 (8), 3213-3220, Article. DOI: 10.7150/thno.96762 Scopus.

  • Guo, W.; Wen, X.; Chen, Y.; Zhao, T.; Liu, J.; Tao, Y.; Fu, H.; Wang, H.; Xu, W.; Pang, Y.; et al. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. Acta Pharmaceutica Sinica B 2024, Article. DOI: 10.1016/j.apsb.2024.05.022 Scopus.

  • Fan, X.; Zhang, H.; Wang, Z.; Zhang, X.; Qin, S.; Zhang, J.; Hu, F.; Yang, M.; Zhang, J.; Yu, F. Diagnosing postoperative lymph node metastasis in thyroid cancer with multimodal radiomics and clinical features. Digital Health 2024, 10, Article. DOI: 10.1177/20552076241233244 Scopus.

  • Cheng, X.; Hou, G.; Zheng, R.; Zhang, J.; Wang, X. Detection of Small Brain Metastases by 18F-Thretide PET/CT in Clear Cell Renal Cell Carcinoma. Clinical Nuclear Medicine 2024, Article. DOI: 10.1097/RLU.0000000000005523 Scopus.

  • Chen, Y.; Zheng, S.; Zang, J.; Shao, Z.; Tu, D.; Liu, Q.; Chen, X.; Miao, W.; Zhang, J. [68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study. European Journal of Nuclear Medicine and Molecular Imaging 2024, Article. DOI: 10.1007/s00259-024-06930-4 Scopus.

  • Chen, X.; Zhang, Z.; Wang, L.; Zhang, J.; Zhao, T.; Cai, J.; Dang, Y.; Guo, R.; Liu, R.; Zhou, Y.; et al. Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (8), 2338-2352, Article. DOI: 10.1007/s00259-024-06661-6 Scopus.

  • Chen, L.; Zhang, J.; Chi, C.; Che, W.; Dong, G.; Wang, J.; Du, Y.; Wang, R.; Tian, J.; Ji, N.; et al. Lower-grade gliomas surgery guided by GRPR-targeting PET/NIR dual-modality image probe: a prospective and single-arm clinical trial. Theranostics 2024, 14 (2), 819-829, Article. DOI: 10.7150/thno.91554 Scopus.

  • Chen, J.; Pang, Y.; Liao, X.; Zhou, Y.; Luo, Q.; Wu, H.; Zuo, C.; Zhang, J.; Lin, Q.; Chen, X.; et al. Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2024, Article. DOI: 10.1007/s00259-024-06874-9 Scopus.

  • Baum, R. P.; Wang, P.; Jakobsson, V.; Zhao, T.; Schuchardt, C.; Khong, P. L.; Zhang, J. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics 2024, 14 (1), 133-142, Article. DOI: 10.7150/thno.88619 Scopus.

  • Baum, R. P.; Novruzov, E.; Zhao, T.; Greifenstein, L.; Jakobsson, V.; Perrone, E.; Mishra, A.; Eismant, A.; Ghai, K.; Klein, O.; et al. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides. Seminars in Nuclear Medicine 2024, 54 (4), 537-556, Review. DOI: 10.1053/j.semnuclmed.2024.05.010 Scopus.

  • Baum, R. P.; Fan, X.; Jakobsson, V.; Yu, F.; Schuchardt, C.; Chen, X.; Zhang, J. Long-term Nephrotoxicity after PRRT: Myth or Reality. Theranostics 2024, 14 (2), 451-459, Article. DOI: 10.7150/thno.92487 Scopus.

  • Baum, R. P.; Fan, X.; Jakobsson, V.; Schuchardt, C.; Chen, X.; Yu, F.; Zhang, J. Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51 (4), 1136-1146, Article. DOI: 10.1007/s00259-023-06544-2 Scopus.

2023

  • Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, Shao Z, Wang C, Chen H, Chen Y, Zhu Z, Miao W, Chen X, Zhang J. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023 Oct 21. PMID: 37864592.

  • Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, Pang Y, Guo W, Sun L, Wu H, Xu P, Su B, Zhang J, Chen X, Chen H. Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study. Clin Cancer Res. 2023 Oct 6. PMID: 37801296.

  • Zang J, Lin R, Wen X, Wang C, Zhao T, Jakobsson V, Yang Y, Wu X, Guo Z, Chen X, Zhang J, Miao W. A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers. Clin Nucl Med. 2023 Oct 1;48(10):861-868.

  • Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, Wu H, Zhang J, Chen X, Chen H. Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT. J Nucl Med. 2023 Oct 26.

  • Li C, Chen X, Zhang J. Comment on: "Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors". J Pharm Anal. 2023 Sep;13(9):958-959.

  • Lin R, Wang C, Chen S, Lin T, Cai H, Chen S, Yang Y, Zhang J, Xu F, Zhang J, Chen X, Zang J, Miao W. [68Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2023 Sep 20.

  • Tao Y, Jakobsson V, Chen X, Zhang J. Exploiting Albumin as A Versatile Carrier for Cancer Theranostics. Acc Chem Res. 2023 Sep 19;56(18):2403-2415.

  • Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, Zhang J, Chen X, Chen H. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023 Aug 21;13(13):4694-4710.

  • Zhang J, Zhao T, Jakobsson V, Chen X. Clinical Translation of RadioTheranostics for Precision Oncology. Nat Rev Bioeng. Aug 2023;1:612-614.

  • Zhang J, Schuchardt C, Chen X, Baum RP. Rapid Tumor Washout of 177Lu-PSMA Radioligand in Renal Cell Carcinoma. Clin Nucl Med. 2023 Aug 1;48(8):732-734.

  • Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, Jing H, Zhuang H, Li F. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3097-3106.

  • Wang P, Li T, Li F, Zhang J, Jing H. Bladder paraganglioma detection with [18F]MFBG PET/CT: a superior alternative to [68Ga]Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3147-3148.

  • Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2846-2860.

  • Jiang Y, Liu Q, Wang G, Zhang J, Zhu Z, Chen X. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Clin Nucl Med. 2023 Jun 1;48(6):e289-e293.

  • Wang R, Jakobsson V, Wang J, Zhao T, Peng X, Li B, Xue J, Liang N, Zhu Z, Chen X, Zhang J. Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023 May 15;13(9):2979-2992.

  • Zhang Y, Wang L, Zhang C, Zhang J, Yuan L, Jin S, Zhou W, Guan X, Kang P, Zhang C, Tian J, Chen X, Li D, Jia W. Preclinical assessment of IRDye800CW-labeled gastrin-releasing peptide receptor-targeting peptide for near infrared-II imaging of brain malignancies. Bioeng Transl Med. 2023 May 9;8(4):e10532.

  • Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, Fan X, Zhang J, Zhu Z, Chen X. A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2023 Apr;64(4):611-617.

2022

  • Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, Zeng X, Zhang J, Wu X, Zhang X, Miao W, Xu P, Guo Z, Zhang J, Chen X. Synthesis, preclinical evaluation, and radiation dosimetry of a dual-targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics. 2022 Oct 9;12(16):7180-7190.

  • Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhang J, Zhu Z, Chen X. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022 Sep 6;12(15):6437-6445.

  • Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022 Dec 7;9:1034315.

  • Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022 Aug;63(8):1199-1207.

  • Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022 Mar;63(3):415-423.

  • Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J, Zhao L, Sun L, Wu H, Chen X, Lin Q, Chen H. Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1360-1373.

2021

  • Schuchardt C, Zhang J, Kulkarni HR, Chen X, Mueller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry. J Nucl Med. 2021 Dec 9:jnumed.121.262713.

  • Zhang J, Kulkarni HR, Baum RP. 225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation. Clin Nucl Med. 2021 Dec 1;46(12):1030-1031. 

  • Baum RP, Zhang J, Schuchardt C, Mueller D, Maecke H. First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy. J Nucl Med. 2021 Nov;62(11):1571-1581

  • Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results. J Nucl Med. 2021 Jun 24:jnumed.120.259192.

Previous

  • He K, Chi C, Li D, Zhang J, Niu G, Lv F, Wang J, Che W, Zhang L, Ji N, Zhu Z, Tian J, Chen X. Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery. Bioeng Transl Med. 2020 Aug 31;6(1):e10182.

  • Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Prognostic Value of 18F-FDG PET/CT in a Large Cohort of 495 Patients with Advanced Metastatic Neuroendocrine Neoplasms (NEN) Treated with Peptide Receptor Radionuclide Therapy (PRRT). J Nucl Med. 2020 Nov;61(11):1560-1569.

  • Zhang J, Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Langbein T, Baum RP. 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney. J Nucl Med. 2019 Nov;60(11):1579-1586.

  • Zhang J, Tian Y, Li D, Ji N, Niu G, Lang L, Li F, Liu Y, Zhu Z, Chen X. 68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2152-2162.

  • Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med. 2019 Mar;60(3):377-385.

  • Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, Meulen NP, Müller C, Mäcke H, Baum RP. From Bench to Bedside – The Bad Berka Experience With First-in-Human Studies. Semin Nucl Med. 2019 Sep;49(5):422-437.

  • Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. J Nucl Med. 2018 Nov;59(11):1699-1705.

  • Zhang J, Mao F, Niu G, Peng L, Lang L, Li F, Ying H, Wu H, Pan B, Zhu Z, Chen X. 68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer. Theranostics. 2018 Jan 1;8(4):1121-1130.

  • Li D, Zhang J, Chi C, Xiao X, Wang J, Lang L, Ali I, Niu G, Zhang L, Tian J, Ji N, Zhu Z, Chen X. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN. Theranostics. 2018 Apr 3;8(9):2508-2520.

  • Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X. PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2018 Jun;59(6):922-928.

  • Long X, Zhang J, Zhang D, Gao C, Chi C, Yang Y, Xue H, Lang L, Niu G, Zhu Z, Li F, Chen X. Microsurgery guided by sequential preoperative lymphography using 68Ga-NEB PET and MRI in patients with lower-limb lymphedema. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1501-1510.

  • Zhang J, Niu G, Lang L, Li F, Fan X, Yan X, Yao S, Yan W, Huo L, Chen L, Li Z, Zhu Z, Chen X. Clinical translation of a dual integrin αvβ3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD. J Nucl Med. 2017 Feb;58(2):228-234.

  • Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, Niu G, Li F, Chen X. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. J Nucl Med. 2016 Jan;57(1):9-14.

  • Zheng K, Liang N, Zhang J, Lang L, Zhang W, Li S, Zhao J, Niu G, Li F, Zhu Z, Chen X. 68Ga-NOTA- PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer. J Nucl Med. 2015 Dec;56(12):1823-1827.

  • Zhang J, Lang L, Zhu Z, Li F, Niu G, Chen X. Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB. J Nucl Med. 2015 Oct;56(10):1609-1614.

Contact Us

Questions?
Contact Me Any Time

Yong Loo Lin School of Medicine National University of Singapore

Department of Diagnostic Radiology

National University Hospital, 

Main Building, Lobby F, Level 4

#04-398, DDI Library

5 Lower Kent Ridge Road

Singapore 119074

j.zhang@nus.edu.sg

  • White LinkedIn Icon

©2035 by Andrew Tessman Translations. Powered and secured by Wix

bottom of page